HLA-E and neoplasm: The inhibitory receptors NKG2A and the killer-cell immunoglobulin-like receptors (KIRs), through the binding with their respective ligands HLA-E and HLA-A on tumor cells, suppress cytokine secretion and hamper direct cytotoxicity of NK cells against target cells (31, 42).